Related Experiment Video
Updated: Jan 27, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
MicroRNA-26b acts as an antioncogene and prognostic factor in cervical cancer
Lihong Wang1, Wen Wang1, Yuanyuan Wu1
1Department of Pathology, Shangluo Central Hospital, Shangluo, Shaanxi 726000, P.R. China.
Abstract:
Cervical cancer is the second most frequent malignant neoplasm in women all over the world. MicroRNA-26b (miR-26b) has been reported to be downregulated and play a great role in many malignancies, nevertheless, there are scarce studies on cervical cancer. The purpose of the present study was to detect how miR-26b is involved in cervical carcinoma. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was utilized to detect the expression levels of miR-26b and Jagged1 (JAG1) mRNA. Transwell assay was applied to calculate the cell migration and invasion capacity. Luciferase reporter assay was employed to determine JAG1 as a target of miR-26b. The results revealed that miR-26b is downregulated in cervical cancer tissues and cells compared with paracancerous tissues and normal cervical epithelial cells. The low expression of miR-26b in cervical cancer demonstrated that miR-26b inhibits cell migration and invasion, as measured by Transwell assay. JAG1 was verified to be a target of miR-26b and have a negative correlation with miR-26b, as detected by luciferase reporter assay. In addition, miR-26b was found to suppress cell migration and invasion via mediating JAG1 expression, which impact is partially reversed by JAG1. In conclusion, miR-26b suppresses cell migration and invasion of cervical cancer through directly targeting JAG1. It is suggested that miR-26b/JAG1 axis may present a new target for the treatment of cervical cancer.
Insights
MicroRNA-26b (miR-26b) is downregulated in cervical cancer, inhibiting tumor cell migration and invasion. Targeting the miR-26b/Jagged1 (JAG1) axis offers a potential new treatment strategy for cervical cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cervical cancer is a leading global malignancy in women.
- MicroRNA-26b (miR-26b) is frequently downregulated in various cancers, but its role in cervical cancer is understudied.
- Understanding miR-26b's function is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the role of miR-26b in cervical carcinoma.
- To determine the relationship between miR-26b and Jagged1 (JAG1) in cervical cancer cells.
- To explore the potential of the miR-26b/JAG1 axis as a therapeutic target.
Main Methods:
- Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for gene expression analysis.
- Transwell assays to assess cell migration and invasion.
- Luciferase reporter assays to validate direct targeting of JAG1 by miR-26b.
Main Results:
- miR-26b expression was significantly downregulated in cervical cancer tissues and cells compared to normal controls.
- Reduced miR-26b expression correlated with increased cell migration and invasion.
- JAG1 was identified as a direct target of miR-26b, with inverse expression correlation.
- miR-26b suppressed cervical cancer cell migration and invasion by targeting JAG1, an effect partially reversed by JAG1 overexpression.
Conclusions:
- miR-26b acts as a tumor suppressor in cervical cancer by inhibiting cell migration and invasion.
- The miR-26b/JAG1 axis represents a promising novel therapeutic target for cervical cancer treatment.
Related Concept Videos
MicroRNAs
MicroRNAs
Forces Acting on Chromosomes
Microtubules and motor proteins exert two types of forces on...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Drugs Acting on Autonomic Ganglia: Blockers

